Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05585632 · ClinicalTrials.gov registry record · Phase 1
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 392
- Enrollment target
NCT05585632: Completed Phase 1 study, sponsored by ModernaTX.
NCT05585632 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 392 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (553% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05585632, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 392 participants
- Enrollment target
Study Summary
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older participants.
Interventions
- BIOLOGICAL mRNA-1345
- BIOLOGICAL mRNA-1010
- BIOLOGICAL mRNA-1273.214
- BIOLOGICAL mRNA-1045
- BIOLOGICAL mRNA-1230
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2024-02-28 |
| Phase | Phase 1 |
What the finished NCT05585632 record still lists
NCT05585632 is an interventional study that assigns participants to a tested intervention. The registered 392 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (553% higher).
The record links to 0 conditions, and to 5 interventions - of which mRNA-1345 is the first listed.
NCT05585632 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05585632 about?
NCT05585632 is a clinical study titled "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old". The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older particip...
What is the current status of trial NCT05585632?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 392 participants. The study started on 2022-10-14. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT05585632?
The interventions under investigation include: mRNA-1345 (BIOLOGICAL), mRNA-1010 (BIOLOGICAL), mRNA-1273.214 (BIOLOGICAL), mRNA-1045 (BIOLOGICAL), mRNA-1230 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05585632?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05585632's enrollment target sits among peer trials
392 77th of 2000 higher than 1,923 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06397703 · 392 participants · Phase 2
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI